卡瑞利珠单抗联合贝伐珠单抗及化疗在非鳞非小细胞肺癌肝转移患者中的疗效  

Effect of Camrelizumab Combined with Bevacizumab and Chemotherapy in the Treatment of Patients with Liver Metastasis of Nonsquamous Non-small Cell Lung Cancer

作　　者：王逸飞 邓建华 刘晓学 WANG Yifei;DENG Jianhua;LIU Xiaoxue(Department of OncologyⅢ,Jiujiang NO.1 People's Hospital,Jiujiang 332000,China)

机构地区：[1]九江市第一人民医院肿瘤三科,江西九江332000

出　　处：《中国医学创新》2025年第4期1-5,共5页Medical Innovation of China

基　　金：江西省卫生健康委科技计划项目(SKJP202211880)。

摘　　要：目的:探究卡瑞利珠单抗联合贝伐珠单抗及化疗在非鳞非小细胞肺癌肝转移患者中的疗效。方法:将2022年1月—2024年1月九江市第一人民医院的80例非鳞非小细胞肺癌肝转移患者根据随机数字表法分为两组,每组40例。对照组采用贝伐珠单抗及化疗,观察组则采用卡瑞利珠单抗联合贝伐珠单抗及化疗。两组均每21天为1个疗程,连续治疗4个疗程。比较两组的客观缓解率、疾病控制率、毒副反应发生率、治疗前后的T淋巴细胞亚群(CD4^(+)及CD4^(+)/CD8^(+))、肿瘤标志物[神经特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)、甲胎蛋白(AFP)及碱性磷酸酶(ALP)]及细胞凋亡因子[血清可溶性凋亡相关因子(sFas)、可溶性凋亡相关因子配体(sFasL)及B淋巴细胞瘤-2基因(Bcl-2)]。结果:观察组的客观缓解率及疾病控制率均显著高于对照组,毒副反应发生率均显著低于对照组,差异均有统计学意义(P<0.05),治疗前两组的T淋巴细胞亚群、肿瘤标志物及细胞凋亡因子比较,差异均无统计学意义(P>0.05),治疗后观察组的T淋巴细胞亚群均显著高于对照组,肿瘤标志物及细胞凋亡因子均显著低于对照组,差异均有统计学意义(P<0.05)。结论:卡瑞利珠单抗联合贝伐珠单抗及化疗在非鳞非小细胞肺癌肝转移患者中的应用效果较好,有助于机体免疫的调控,且可有效改善细胞凋亡因子。Objective:To investigate the effect of Camrelizumab combined with Bevacizumab and chemotherapy in the treatment of patients with liver metastasis of nonsquamous non-small cell lung cancer.Method:A total of 80 patients with liver metastasis of nonsquamous non-small cell lung cancer in Jiujiang NO.1 People's Hospital from January 2022 to January 2024 were divided into two groups with 40 cases in each group according to the random number table method.The control group was treated with Bevacizumab and chemotherapy,the observation group was treated with Camrelizumab combined with Bevacizumab and chemotherapy.Patients in the two groups were treated for 4 consecutive courses every 21 days as a course of treatment.Then the objective remission rate,disease control rate,toxic side effects rates,T lymphocyte subsets(CD4^(+)and CD4^(+)/CD8^(+)),tumor markers[neuron-specific enolase(NSE),cytokeratin 19 fragments(CYFRA21-1),alpha fetoprotein(AFP)and alkaline phosphatase(ALP)]and apoptosis factors[serum soluble factor-related apoptosis(sFas),soluble factorrelated apoptosis ligand(sFasL)and B-cell lymphoma-2(Bcl-2)]before and after the treatment of two groups were compared.Result:The objective remission rate and disease control rate of observation group were significantly higher than those of control group,the toxic side effects rates were significantly lower than those of control group,the differences were all statistically significant(P<0.05).The T lymphocyte subsets,tumor markers and apoptosis factors of two groups before treatment were compared,the differences were not statistically significant(P>0.05),the T lymphocyte subsets of observation group after treatment were significantly higher than those of control group,the tumor markers and apoptosis factors were significantly lower than those of control group,the differences were all statistically significant(P<0.05).Conclusion:The application effect of Camrelizumab combined with Bevacizumab and chemotherapy in the treatment of patients with liver metastasis of nonsquamous non

关 键 词：卡瑞利珠单抗 贝伐珠单抗 非鳞非小细胞肺癌肝转移 毒副反应 细胞凋亡因子 

分 类 号：R734.2[医药卫生—肿瘤]